216 related articles for article (PubMed ID: 34114922)
41. Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis.
Gao C; Wang J; Li Y; Zhao H; Li R; Hou L; Zhang Y; Tian S; Liang H; Wang C; Chen X; Wang J
Medicine (Baltimore); 2018 Aug; 97(34):e11860. PubMed ID: 30142779
[TBL] [Abstract][Full Text] [Related]
42. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.
Uy N; Singh A; Gore SD; Prebet T
Expert Opin Pharmacother; 2017 Aug; 18(12):1213-1224. PubMed ID: 28675065
[TBL] [Abstract][Full Text] [Related]
43. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
Oran B; Kongtim P; Popat U; de Lima M; Jabbour E; Lu X; Chen J; Rondon G; Kebriaei P; Ahmed S; Andersson B; Alousi A; Ciurea S; Shpall E; Champlin RE
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1618-25. PubMed ID: 24953017
[TBL] [Abstract][Full Text] [Related]
44. A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival.
Garcia JS; Swords RT; Roboz GJ; Jacoby MA; Garcia-Manero G; Hong WJ; Yang X; Zhou Y; Platzbecker U; Steensma DP; Wolff JE; Fenaux P
Leuk Res; 2021 May; 104():106555. PubMed ID: 33705966
[TBL] [Abstract][Full Text] [Related]
45. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X
Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809
[TBL] [Abstract][Full Text] [Related]
46. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents.
Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S56-9. PubMed ID: 26297279
[TBL] [Abstract][Full Text] [Related]
47. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.
Hunter AM; Komrokji RS; Yun S; Al Ali N; Chan O; Song J; Hussaini M; Talati C; Sweet KL; Lancet JE; Padron E; List AF; Sallman DA
Blood Adv; 2021 Feb; 5(4):1017-1028. PubMed ID: 33591325
[TBL] [Abstract][Full Text] [Related]
48. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
49. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
[TBL] [Abstract][Full Text] [Related]
50. Optimizing hypomethylating agents in myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2012 Mar; 19(2):65-70. PubMed ID: 22248878
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Chien KS; Kim K; Nogueras-Gonzalez GM; Borthakur G; Naqvi K; Daver NG; Montalban-Bravo G; Cortes JE; DiNardo CD; Jabbour E; Alvarado Y; Andreeff M; Bose P; Jain N; Kadia TM; Huang X; Sheppard KB; Klingner-Winton C; Pierce SA; Dong XQ; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Br J Haematol; 2021 Nov; 195(3):378-387. PubMed ID: 34340254
[TBL] [Abstract][Full Text] [Related]
52. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
53. Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine.
Ogawa S; Sakamoto T; Matsuoka R; Ishitsuka K; Ogino Y; Sootome A; Makishima K; Yoshida C; Ito Y; Shimizu S; Suyama T; Shinagawa A; Ito T; Obara N; Kusakabe M; Sakata-Yanagimoto M; Miyazaki Y; Nannya Y; Chiba S
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1938. PubMed ID: 38014499
[TBL] [Abstract][Full Text] [Related]
54. Hypomethylating therapy and autoimmunity in MDS: an enigmatic relationship.
Kotsianidis I; Spanoudakis E; Nakou E; Miltiades P; Margaritis D; Tsatalas C; Tzouvelekis A; Oikonomou A
Leuk Res; 2012 Apr; 36(4):e90-2. PubMed ID: 22230300
[No Abstract] [Full Text] [Related]
55. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
Nazha A; Sekeres MA; Garcia-Manero G; Barnard J; Al Ali NH; Roboz GJ; Steensma DP; DeZern AE; Zimmerman C; Jabbour EJ; Zell K; List AF; Kantarjian HM; Maciejewski JP; Komrokji RS;
Leuk Res; 2016 Feb; 41():43-7. PubMed ID: 26777537
[TBL] [Abstract][Full Text] [Related]
57. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.
Zeidan AM; Kharfan-Dabaja MA; Komrokji RS
Curr Opin Hematol; 2014 Mar; 21(2):123-30. PubMed ID: 24335709
[TBL] [Abstract][Full Text] [Related]
58. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
59. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
60. How I treat MDS after hypomethylating agent failure.
Santini V
Blood; 2019 Feb; 133(6):521-529. PubMed ID: 30545832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]